Skip to main content

Table 1 Baseline disease characteristics by background AD therapy

From: A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

  Placebo Neflamapimod
AD therapy (n = 51) No AD therapy (n = 32) AD therapy (n = 46) No AD therapy (n = 32)
Age 73 (7.8) 72.1 (5.9) 72.2 (6.8) 68.9 (5.6)
Gender (% female) 45.1 62.5 47.8 46.9
ApoE4 (% positive) 66.7 71.9 67.4 78.1
HVLT-R Total Recall 13.4 (4.5) 18.3 (4.9) 14.8 (5.1) 18.6 (6.9)
HVLT-R Delayed Recall 1.8 (2.1) 4.0 (3.3) 2.2 (2.4) 4.7 (4.0)
WMS Immediate & Delayed Recall 58.1 (21.8) 84.2 (34.1) 61.7 (25.0) 92.6 (42.0)
CDR sum of boxes 3.7 (1.6) 2.4 (1.5) 3.4 (1.4) 2.6 (1.0)
MMSE 22.7 (2.4) 25.2 (2.7) 22.9 (2.5) 25.1 (2.3)
CSF Aβ40 10583 (3340) 10783 (3162) 11099 (2926) 11259 (3465)
CSF Aβ42 545 (155) 562 (194) 556 (138) 602 (196)
CSF p-tau181 35.5 (14.2) 30.9 (11.0) 37.6 (15.1) 33.4 (14.4)
CSF total tau 360 (126) 316 (97) 378 (132) 337 (116)
CSF neurogranin 477 (238) 427 (160) 510 (224) 469 (161)
CSF NfL 1456 (640) 1230 (694) 1586 (760) 1257 (530)
  1. Mean (SD), except where percentage is shown. CSF levels are shown as pg/mL